We are live on ! Find out more
UL

Ulys LLC Portfolio holdings

AUM $25.4M
1-Year Est. Return 201.03%
This Fund
S&P 500
This Quarter Est. Return
+25.92%
1 Year Est. Return
+201.03%
3 Year Est. Return
-31.51%
5 Year Est. Return
-50.88%
10 Year Est. Return
AUM
$78.1M
AUM Growth
+$16.1M
Cap. Flow
-$2K
Cap. Flow %
-0%
Top 10 Hldgs %
100%
Holding
2
New
Increased
Reduced
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CERE
CERES, INC. COMMON STOCK NEW
CERE
+$2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$78.1M 100%
4,321,214
CERE
2
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
-3,891
Closed -$2K

Similar funds

Ulys LLC's Q3 2016 Portfolio in Review

As of Q3 2016, Ulys LLC held 2 positions worth $78.1M, up 26% from $62M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Ulys LLC's Q3 2016 filing shows 1 closed position. The largest sale was CERES, INC. COMMON STOCK NEW, an estimated $2K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Ulys LLC fully exited CERES, INC. COMMON STOCK NEW in Q3 2016, selling an estimated $2K.
  • Ulys LLC's ten largest holdings make up 100% of its $78.1M portfolio in Q3 2016.
  • Ulys LLC opened 0 new positions and closed 1 in Q3 2016.
  • Ulys LLC's portfolio value rose 26% quarter-over-quarter to $78.1M.

Based on Ulys LLC's 13F filing for Q3 2016, filed 14 Nov 2016.